Dr. Sahib Khalsa, M.D., Ph.D., is Director of Clinical Operations for LIBR, Associate Professor at the Oxley College of Health Sciences at the University of Tulsa, Director at LIBR Float Clinic and Research Center, and Volunteer Faculty Member in the Department of Psychiatry at the University of Oklahoma. Dr. Khalsa’s laboratory studies the role of the brain-body connection in human health; he has published more than 90 peer-reviewed papers and has received research funding from the National Institute of Mental Health (NIMH), National Institute for General Medical Sciences (NIGMS), National Center for Complementary and Integrative Health (NCCIH), the NIH/National Center for Advancing Translational Science (NCATS), the Mind and Life Foundation, and the Brain and Behavior Research Foundation. His research is currently funded by NIMH and LIBR.
Q: The Laureate Psychiatric Hospital and LIBR are known and respected for their work in the fields of identifying, treating, and researching eating disorders like anorexia nervosa; as February is focused on heart health, how does what you study relate to a healthy heart?
A: Many people know about the relaxing experience of floating in water or the value of taking some time each day to pause and be away from the usual hustle and bustle of daily activities. We are currently studying the potential therapeutic impact of a particular form of Reduced Environmental Stimulation Therapy (REST) called Floatation-REST, on mental health in individuals with anxiety disorders, depression, eating disorders, or substance use disorder. Floatation-REST reduces external sensory input to the central nervous system by minimizing environmental stimulation, through the act of floating supine in a pool of water saturated with Epsom salt. In this environment, the density of the salt water allows for effortless floating. The temperature of the air and water is matched to the person’s skin temperature, and visual and auditory stimulation and movement is minimized.
Our research using Floatation-REST (Paper 1) (Paper 2) has shown that it can significantly reduce blood pressure during the float session, especially the diastolic blood pressure, reduce breathing rate, and certain metrics of heart rate variability, suggesting a shift in the autonomic nervous system toward a more relaxed state. Interestingly, Floatation-REST is also associated with enhanced awareness for cardiac and respiratory sensations while reducing anxiety levels in anxious individuals, indicating a paradoxical effect. We have also recently found that Floatation-REST acutely lowers anxiety and stress symptoms and improves some aspects of body image in hospitalized individuals with anorexia nervosa.
Q: How do your present studies take the next steps in studying heart health as it relates to eating disorders?
A: Our ongoing studies are adding to the rigor of prior research by thoroughly characterizing the cardiovascular changes induced by Floatation-REST and examining how neural and physiological changes are associated with its anxiolytic effects. For example, in healthy individuals, we have found that Floatation-REST is associated with a reduced functional coupling of brain activity within the hubs of brain networks most responsible for creating and mapping our sense of self. We also recently found that women with anorexia nervosa show reduced brain-body network connectivity after undergoing a cardiac stress challenge; the less connected these parts of the brain were, the more anxiety, depression, and negative body image the women had. We plan to extend these studies to identify whether changes in similar brain networks helps to explain the beneficial impacts observed with Floatation-REST in individuals with eating disorders.
Q: Do you need people to help you with this new research project?
A: We are conducting several studies looking at the role of the brain-body connection in eating disorders. When an individual receiving treatment with Laureate qualifies for ongoing research studies, they may be offered the opportunity to participate. The clinical team assists in evaluating how participation will support their recovery and whether the individual might benefit from engaging in the study. We also need volunteers not in treatment for an eating disorder to help with this research. If you or someone you know between the ages of 13-40 would like to be one of our paid volunteers, please contact our lab or fill out the form on our website.
Dr. Joan Camprodon - February 7, 2023
"Suicide Circuit Therapeutics: Leveraging the Efficacy of ECT and the Focality of TMS"
William K. Warren, Jr. Frontiers in Neuroscience Lecture
12:00 pm - 1:00 pm Program in the LPCH auditorium (No registration needed)
Dr. Camprodon is inaugural Chief of the Division of Neuropsychiatry and Director of the Laboratory for Neuropsychiatry and Neuromodulation at Massachusetts General Hospital, and Associate Professor of Psychiatry at Harvard Medical School.
Clinically, he is the founding Director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, a member of the Psychiatric Neurosurgery Committee and an attending physician in the Departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He is board-certified in psychiatry and behavioral neurology-neuropsychiatry.
Dr. Camprodon’s research focuses on Neuropsychiatry and Neuromodulation. Methodologically, he uses multimodal combinations of brain stimulation and neuroimaging/neurophysiology to investigate neural circuitry and plasticity in a translational manner. He uses a wide range of noninvasive and invasive neuromodulation techniques including transcranial current stimulation (tCS, e.g. tDCS/tACS), transcranial magnetic stimulation, transcranial photobiomodulation, electroconvulsive therapy and deep brain stimulation. He also uses multimodal functional and structural MRI, EEG and innovative simultaneous combinations of TMS and tDCS/tACS with neuroimaging and neurophysiology. The scope of his research includes basic, translational and clinical projects focused on human circuit neuroscience. Projects in his laboratory address (1) circuit level neuropsychiatric pathophysiology (with an emphasis on transdiagnostic processes and the role of plasticity) and (3) the translational development of tools to support clinical care and decision-making (e.g. biomarkers and treatment development). Critical efforts are geared towards applying the paradigms and methods of human systems/cognitive neuroscience to discover treatment targets that support the development of individualized precision therapeutics, with a focus on image-guided device-based neuromodulation.
Saint Francis Health System designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Psychologists: The Oklahoma State Board of Examiners of Psychologists, the American Psychological Association and the Oklahoma Psychological Association recognize AMA PRA Category 1 credit™. Saint Francis Health System is accredited by the OSMA
For Social Workers: Saint Francis Health System is an approved provider of continuing education for social worker through the Oklahoma State Board of Licensed Social Workers for 1 hour Category 1 Clinical. (CEP Number - 20230007)
For CADCs and LADCs Saint Francis Health System is accredited as a provider of continuing education programs for CADCs and LADCs through the Oklahoma Board of Licensed Alcohol and Drug Counselors. (1 hour)
The LPC/LMFT This event as been approved by the State Board of Behavioral Health Licensure (BBHL) for 1 hour of CE.
For questions , email: Lauren Haguewood at firstname.lastname@example.org